Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy

Med · Published 2026-05-14 · DOI 10.1016/j.medj.2026.101140

Authors (10)

Xudong Ni, Yufan Zhao, Shanshan Wang, Lei Zhong, Xuedong Shi, Xiaomeng Li, Qi Ma, Yi Wu, Dingwei Ye, Yao Zhu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ni, X., Zhao, Y., Wang, S., et al. (2026). Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy. Med. https://doi.org/10.1016/j.medj.2026.101140

Related articles

• A single-cell solution to a transplant mystery · Med · 2026 · Same journal
• Five trials reshaping multiple myeloma · Med · 2026 · Same journal
• Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity · Med · 2026 · Same journal
• Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation · Med · 2026 · Same journal
• Resectability redefined: Lessons from quadruple therapy in HCC · Med · 2026 · Same journal
• Rethinking parenteral nutrition as supportive therapy for neonatal sepsis · Med · 2026 · Same journal
• Rewriting the sarcomere: Gene therapy approaches for hypertrophic cardiomyopathy from bench to bedside · Med · 2026 · Same journal
• Power and sample-size estimation in human microbiome research · Med · 2026 · Same journal
• Building on CD19 based therapy for relapse or refractory follicular lymphoma · Med · 2026 · Same journal
• Ethics of gene therapy · Med · 2026 · Same journal